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Abstract
The goal of this study was to compare outcomes and costs of two management strategies for non-ventilator-associated nosocomial
pneumonia (NP) in a medical ward. In this single-centre study, NP patients (n = 68) were randomized to receive non-invasive manage-
ment (NIM) with immediate empirical antibiotic treatment (n = 34), or invasive management (IM) based on protected brush sampling of
specimens (n = 34). The economic analysis adopted the hospital’s perspective and took into account only direct costs. Baseline charac-
teristics did not differ signiﬁcantly between the two patient groups. The most frequently isolated organisms were Staphylococcus (25.4%),
Streptococcus (23.7%) and Pseudomonas (18.6%) species. The 28-day clinical cure rate did not differ notably between the two groups
(NIM, 79.4%; IM, 73.5%). Mortality at 28 days tended to be lower in the NIM group (10.0% vs. 21.8%). Mean antibiotic costs were
lower in the IM group (€194 ± 355 vs. €300 ± 335, p <0.001) but overall management costs were similar (respectively, €367 ± 355 and
€346 ± 363 in the IM and NIM groups, p = 0.08). With respect to both outcome and cost, this study does not support routine manage-
ment of NP in medical wards using invasive procedures.
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Introduction
Nosocomial pneumonia (NP) is the leading nosocomial infec-
tion in intensive-care units (ICUs) and the second most frequent
nosocomial infection in non-surgical hospital wards in France [1].
Several studies have focused on the management of NP in
ICUs [2–4], but there are few data on the management of
NP in non-ventilated patients in medical wards [5,6].
The diagnosis of ventilator-associated pneumonia (VAP)
can be based on either clinical ﬁndings or results of invasive
methods, including culture of protected specimen brush
(PSB) or bronchoalveolar lavage samples [3]. One multicen-
tre randomized trial showed that an invasive strategy based
on quantitative bronchoscopic specimen culture improved
early survival among VAP patients and prevented early organ
failure [7], but it is not known whether this strategy is bene-
ﬁcial for NP patients in medical wards.
Most studies of NP in non-ICU settings suffer from the
absence of a deﬁnitive diagnosis. PSB might help to improve
patient management by deﬁnitively diagnosing pulmonary infec-
tion and by identifying the responsible pathogen [6]. Indeed,
it was previously found that PSB led to improved diagnosis
and treatment of NP in non-ventilated patients [8]. An invasive
NP management strategy may also lead to more appropriate
antibiotic use and thereby reduce costs [7,9]. However, this
requires specialized equipment and trained personnel, is
expensive, and may in itself be harmful in some cases [10].
These drawbacks must be seen in the light of the better out-
come of NP in non-ICU patients than in ICU patients [5,6,8].
The aims of this single-centre randomized study were to
compare, among NP patients hospitalized in a medical ward,
the clinical outcomes and costs of two management strate-
gies, consisting of immediate empirical antibiotic treatment
(non-invasive management (NIM)) or of treatment guided by
PSB (invasive management (IM)).
Materials and Methods
Study period and setting
Patients were enrolled prospectively, between January 2002
and December 2004. The setting was Forcilles Medical
Hospital, a 411-bed facility with a cancer treatment unit and
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several intermediary-care units for rehabilitation of patients
with cardiac, metabolic and chronic respiratory diseases.
Study design
The following inclusion criteria were used: recent and persis-
tent inﬁltration on the chest radiograph and at least two of
the following—body temperature ‡38C or <36C, abnor-
mal leukocyte count, purulent tracheobronchial secretions,
and symptom onset either after 72 h of hospitalization or on
admission to Forcilles hospital following a long stay in
another hospital. Patients with immunosuppression, patients
considered unsuitable for bronchoscopy by the attending
physician and patients with a life-expectancy of <3 months
were excluded. As bacterial colonization of distal airways has
been found in about 50% of long-term tracheostomized
patients [11], tracheostomized patients were also excluded.
The following characteristics were recorded at enrolment:
age and gender; comorbid illnesses, including the assessment
of the McCabe and Jackson score [12] and the Charlson–
Deyo score [13]; length of hospitalization before NP onset;
body temperature; prior antibiotic treatment, including the
antibiotic compound used, or the period without antibiotic
treatment prior to enrolment; the leukocyte count; time
from symptom onset to antibiotic therapy; the extent of
radiographic chest abnormalities; PaO2, FIO2, the PaO2/FIO2
ratio (in spontaneously breathing patients, the PaO2/FIO2 ratio
was calculated assuming that room air FIO2 was 0.21 [14]);
and the presence and aspect of respiratory secretions.
Patients were randomly assigned, by using a random num-
ber table, to either the IM or the NIM strategy. The IM
strategy included immediate bronchoscopy with PSB sam-
pling, i.e. retrieval of bronchoscopic specimens <24 h after
clinical diagnosis of NP. Decisions concerning patient man-
agement (whether to start antibiotic treatment prior to PSB
results) and the choice of antibiotic(s) were made by the
attending physicians, but they were advised to base initial
treatment on the clinical condition of the patient and on the
Gram stain result of the PSB specimen (available 4–6 h later
on the same day) and to modify the treatment, if necessary,
according to the culture results. Initial antimicrobial therapy
was deemed appropriate when the period between the
establishment of the diagnosis of NP and the subsequent
administration of antibiotics was 24 h or less, and when all
causative pathogens were susceptible in vitro to at least one
of the antibiotics of the applied regimen [15]. Bronchoscopy
was performed under local xylocaine anaesthesia of the
upper airways. PSB was performed as described by Wimber-
ley et al. [16]. Brieﬂy, a plugged telescoping catheter brush
was inserted through the working channel and advanced 2–
3 cm beyond the tip of the bronchoscope. The distal plug
was then ejected, and the brush was advanced beyond the
tip of the inner cannula, 3–4 cm into the bronchus, and then
gently rotated and retracted into the inner cannula. The PSB
sample was processed in the laboratory. Lung infection was
distinguished from colonization by using a cut-off of
103 CFU/mL [8]. In the NIM strategy, patients received
empirical antibiotic treatment, the drug(s) and regimen being
chosen by their attending physician. It was recommended
that the initial regimen comply with the American Thoracic
Society (ATS) guidelines [2], but no other attempt was made
to inﬂuence the choice of the antibiotic regimen.
Three evaluations were performed, at 48–72 h, 14–16 days
and 28 days after enrolment. The clinical response at the
ﬁrst evaluation was considered inadequate if the outcome
was one of the following: death, persistent body temperature
‡38C and purulent tracheobronchial secretions, persistently
abnormal leukocyte cell count, or worsening of pulmonary
inﬁltrates on the chest radiograph (conﬁrmed independently
by a radiologist blinded to the treatment group). Patients
with inadequate responses were re-examined to search for
an extrapulmonary site of infection, and to rule out conges-
tive heart failure, atelectasis and pulmonary thromboembo-
lism. If these diagnoses were ruled out, patients underwent
bronchoscopy with PSB, and antibiotic therapy was modiﬁed
according to the pathogen(s) isolated. Clinical cure (disap-
pearance of all signs and symptoms of NP by day 16, without
re-occurrence by day 28) and vital status were assessed at
days 14–16 and 28.
The local ethics committee approved the study. Informed
consent for the study protocol, including possible bronchos-
copy, was obtained in person from each patient.
Cost analysis
The economic analysis adopted the hospital’s perspective
and took into account only direct costs (i.e. consumption of
healthcare resources). Indirect costs (e.g. lost income) and
intangible costs (e.g. pain and suffering) were not assessed.
Direct costs of managing NP included physician fees and the
cost of nursing time for ﬁbreoptic bronchoscopy. These
costs were calculated from the general French fee schedule
(Nomenclature Ge´ne´rale des Actes Professionnels) [17]. The
cost of the PSB device and the bacteriological tests was
obtained from the microbiology laboratory. Information on
antibiotic use was retrieved from the patients’ records, and
the cost of antibiotics reﬂected actual hospital pharmacy
costs. Costs are expressed in euro (€).
Statistical methods
Quantitative data are expressed as mean ± SD. The chi-
square test was used to compare categorical variables, and a
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t-test was used to compare quantitative variables. Cost data
were not normally distributed (Kolmogorov–Smirnov test,




During the study period, 199 non-ventilated patients were
considered for inclusion. Exclusion criteria were present in
85 cases (tracheostomy in 71 cases), and 46 patients did not
meet all the inclusion criteria. The remaining 68 patients
were randomized between the NIM strategy (n = 34) and
the IM strategy (n = 34). The two groups (Table 1) did not
differ signiﬁcantly, except that PaO2/FIO2 was lower in the IM
group (290.1 ± 61.6 mmHg as compared to
321.8 ± 71.2 mmHg, p = 0.054).
Ten patients in each group received antibiotic treatment
before inclusion, because of fever or suspected sepsis. The
antibiotics were amoxycillin–clavulanate (n = 7), ciproﬂoxacin
(n = 3), co-trimoxazole (n = 2) and metronidazole (n = 1) in
the NIM group, and ciproﬂoxacin (n = 4), vancomycin
(n = 4), aminoglycosides (n = 3), amoxycillin–clavulanate
(n = 3), third-generation cephalosporins (n = 3) and pristina-
mycin (n = 2) in the IM group. Treatment had been discon-
tinued 47 ± 61 h (range: 0–192 h) before inclusion in the
NIM group and 55 ± 41 h (range: 0–120 h) in the IM group
(p = 0.72).
All patients in the IM group underwent immediate bron-
choscopy. In the NIM group, nine patients who failed to
respond to treatment subsequently underwent bronchos-
copy. In this group, bronchoscopy was more frequently per-
formed in patients who had received antibiotics before
inclusion (6/10, 60.0%) than in other patients (3/24, 12.5%,
p = 0.004). Five of these six patients had been receiving anti-
biotics within 3 days before enrolment, and in three patients
the PSB culture was negative. In the IM group, ten patients
were already on antibiotics at the time of enrolment, seven
of ten receiving this therapy within the 3 days before inclu-
sion. PSB culture was negative in three of these seven
patients.
Bronchoscopy was not associated with death or serious
adverse events in any case. Minor adverse events occurred
in eight patients in the IM group and two patients in the
NIM group (p = 0.93), including mild oxygen desaturation
(six and one case(s), respectively) and minor bleeding (two
and one case(s), respectively).
Microbiological results and antibiotic regimens
Cultures were positive in 24 of 34 patients (70.6%) in the IM
group (nine monomicrobial and 15 polymicrobial infections)
and in ﬁve of nine patients (55.6%) in the NIM group (three
monomicrobial and two polymicrobial infections) (Table 2).
Among the four patients in the NIM group in whom the PSB
culture was negative, one was not available for further fol-
low-up, and in the remaining three patients an extrapulmo-
nary cause of infection was eventually identiﬁed. The
diagnostic yield of PSB did not signiﬁcantly differ according
to a prior antimicrobial therapy. Among the 43 patients in
whom a PSB sampling was performed, the PSB culture result
was positive in nine of 16 patients who had received prior
antimicrobial therapy as opposed to 20 of 27 patients with-
out prior antimicrobial therapy (p = 0.23, not signiﬁcant).
Negativity of PSB culture was found in three of ﬁve patients
in the NIM group and three of seven patients in the IM
group who had received prior antimicrobial therapy within
the 3 days of inclusion, which may in part explain this fact.
The most frequently isolated organisms were Staphylococcus
(25.4%), Streptococcus (23.7%) and Pseudomonas (18.6%) spe-
cies. In two cases, PSB yielded yeasts (Candida albicans and
Candida glabrata), along with other potential pathogens.




group (n = 34)
Invasive
management
group (n = 34) p
Age (years) of patient 65.9 ± 11.4 65.8 ± 11.3 0.97
Sex (male : female) of patient 27 : 7 25 : 9 0.57
Length of stay, from
admission to NP (days)
33.0 ± 28.1 34.6 ± 42.9 0.85
NP
Early onset 3 (8.8) 8 (23.5)
Late onset (‡7 days) 31 (91.2) 26 (76.5) 0.10
Underlying risk factor for NPb
COPD 7 (20.6) 7 (20.6) 1
Neoplasm 23 (67.6) 24 (70.6) 0.79
Chemotherapy 4 (11.8) 7 (20.6) 0.60
Radiotherapy 3 (8.8) 1 (2.9) 0.30
Diabetes mellitus 3 (8.8) 4 (11.8) 0.69
History of aspiration 6 (17.6) 5 (14.7) 0.93
Recent surgery 6 (17.6) 3 (8.8) 0.49
Alcoholism 3 (8.8) 1 (2.9) 0.30
Malnutrition 3 (8.8) 3 (8.8) 1
McCabe–Jackson score
Non-fatal 13 (38.2) 14 (41.2)
Ultimately fatal 21 (61.8) 20 (58.8) 0.84
Charlson–Deyo score
0 6 (17.6) 6 (17.6)
1–2 22 (64.7) 26 (76.5)
3–4 5 (14.8) 2 (5.9) 0.45
‡5 1 (2.9) 0
Temperature (C) 38.6 ± 0.6 38.8 ± 0.6 0.17
Leukocyte count (cells/mm3) 12 980 ± 6978 11 305 ± 7987 0.36
Polynuclear forms (%) 81.8 ± 9.1 76.9 ± 13.2 0.08
PaO2 (mmHg) 69.8 ± 11.9 67.9 ± 14.5 0.56
PaO2/FIO2 (mmHg) 321.8 ± 71.2 290.1 ± 61.6 0.054
PaCO2 (mmHg) 38.9 ± 10.9 37.4 ± 7.0 0.50
pH 7.43 ± 0.05 7.44 ± 0.04 0.37
NP, nosocomial pneumonia; COPD, chronic obstructive pulmonary disease.
aData are presented as mean ± standard deviation or n (%).
bPatients with possible multiple risk factors.
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All the patients in the NIM group received antibiotics, as
compared to 26 of 34 (76.5%) of the patients in the IM
group (p = 0.003). There was no signiﬁcant difference in the
antibiotics received. Six patients in each group received a
second line of antibiotics (Table 3), which was based on the
ﬁnal PSB results in two patients in the NIM group (Pseudomo-
nas aeruginosa, n = 1; Serratia marcescens, n = 1).
In the NIM group, the initial antimicrobial therapy was
adequate in four of ﬁve patients in whom culture of PSB
was positive, and inadequate in one. This therapy was given
for a total of 7 days, from the beginning of initial therapy
to the result of the PSB culture. In the IM group, the ini-
tial antimicrobial therapy was adequate in 20 of 26 patients.
Among the six patients who received a second-line treat-
ment, the delay in its administration ranged from <24 h
(n = 1), to 1 day (n = 1), 2 days (n = 2) or 3 days (n = 2).
In the two latter cases, the great delay may be explained
by delays in writing the antibiotic prescription and in the
administration of antibiotics after the initial order was writ-
ten.
With regard to the ten patients in each group who
received antimicrobial treatment before inclusion, in the NIM
group eight of ten patients were kept on their initial regimen
and two of ten received second-line therapy (one patient
received antibiotic treatment within 3 days of inclusion); in
the IM group, antimicrobial therapy was omitted in four of
ten patients, ﬁve of ten were kept on their initial regimen,
and one of ten received a second-line therapy (this patient
TABLE 2. Bronchoscopy results (microorganisms isolated at concentrations ‡103 CFU/mL from 43 protected specimen
brushes (PSBs) performed in nine patients in the non-invasive management group and 34 patients in the invasive
management group)
Total, n (%)
Non-invasive management group, n Invasive management group, n
Monomicrobial Polymicrobial Monomicrobial Polymicrobial
Gram-positive bacteriaa 21 (48.8) 2 1 7 8
Positive PSB – 3 2 9 15
Gram-negative bacteria 25 (42.4) 2 1 3 19
Pseudomonas spp. 11 (18.6) 1 1 0 9
Klebsiella spp. 5 (8.5) 0 0 1 4
Haemophilus spp. 5 (8.5) 0 0 2 3
Escherichia coli and other Enterobacteriaceae 3 (5.1) 1 0 0 2
Neisseria spp. 1 (1.7) 0 0 0 1
Gram-positive bacteria 32 (54.2) 1 3 6 22
Staphylococcus spp. 15 (25.4) 0 1 4 10
Streptococcus spp. 14 (23.7) 1 1 2 10
Corynebacterium spp. 3 (5.1) 0 1 0 2
Fungi 2 (3.4) 0 0 0 2
aThe ﬁnal result of PSB culture was negative in one patient in the non-invasive management group and in two patients in the invasive management group.
TABLE 3. Antibiotic regimens prescribed in the patients studied
Non-invasive management group (n = 34) Invasive management group (n = 34)
Initial
regimen
(n = 34) Subsequent regimen (n = 6)
Initial
regimen
(n = 26) Subsequent regimen (n = 6)
No antibiotic therapy 0 8
Single-drug therapy 8 13
b-Lactam 4 0 7 3 (third-generation cephalosporin
plus aminoglycoside)
Third-generation cephalosporin 2 1 (b-lactam) 2 1 (third-generation cephalosporin
plus aminoglycoside)
Quinolone 2 1 (third-generation cephalosporin
plus aminoglycoside)
2 1 (streptogramin)
Streptogramin 0 0 1 0
Vancomycin 0 0 1 0
Multidrug therapy 26 13
b-Lactam plus quinolone 17 2 (third-generation cephalosporin
plus aminoglycoside)
5 1 (third-generation cephalosporin
plus aminoglycoside plus vancomycin)
b-Lactam plus other antimicrobial agents 3 1 (quinolone plus other
antimicrobial agent)
0
Quinolone plus other antimicrobial agents 1 0 1 0
Third-generation cephalosporin plus
aminoglycoside plus vancomycin
5 1 (b-lactam plus quinolone) 5 0
Other combination therapy 0 0 2 0
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received antibiotic treatment within 3 days of inclusion).
However, given the small samples involved, these results
should be interpreted cautiously.
Outcomes (Fig. 1)
On day 3, the clinical response was considered inadequate in
three of 34 patients in the IM group (three deaths) and in
nine of 34 patients in the NIM group; the latter nine patients
then underwent bronchoscopy with PSB (Table 4).
On day 28, six patients (two in the IM group and four in
the NIM group) were not available for follow-up (transfer to
another hospital for surgery in ﬁve cases, and premature dis-
charge for family reasons in one case). The 28-day clinical
cure rate did not differ between the two groups (NIM,
79.4%; IM, 73.5%).
There was a non-signiﬁcant trend towards lower mortality
rates in the NIM group on day 3 (2.9% vs. 8.8%) and day 28
(10.0% vs. 21.9%) (Table 4).
All deaths were directly related to NP. However, in the
NIM group, two patients died without having undergone
bronchoscopy; therefore, NP was ruled out in neither
case. The alternative diagnoses of evolutive metastatic lung
cancer (n = 1) and histiocytosis X (n = 1) were estab-
lished.
Of the eight IM patients who did not receive antibiotics,
one died within hours of bronchoscopy, a non-pathogenic
microorganism was isolated in one patient, and culture was
negative in the other six cases. In the IM group, the mortality
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FIG. 1. Numbers of patients who underwent bronchoscopy in whom nosocomial pneumonia was bacteriologically conﬁrmed, and in whom anti-
microbial therapy was instituted or adjusted. n.a., not available; NIM, non-invasive management; IM, invasive management; PSB, protected speci-
men brush.
TABLE 4. Outcome endpoints in the two study groups
Non-invasive
management
group (n = 34)
Invasive
management
group (n = 34) p
Length of stay after
inclusion in the study (days)
34.5 ± 34.9 32.9 ± 28.4 0.83
Patient not available for follow-up
Day 3 0/34 0/34 1
Day 14 3/34 (8.8) 2/34 (5.9) 0.64
Day 28 4/34 (11.8) 2/34 (5.9) 0.39
Mortality
Day 3 1/34 (2.9) 3/34 (8.8) 0.30
Day 14 2/31 (6.5) 5/32 (15.6) 0.25
Day 28 3/30 (10.0) 7/32 (21.9) 0.20
Clinical failure at day 3 9/34 (26.5) 3/34 (8.8) 0.06
Clinical cure at day 28 27/34 (79.4) 25/34 (73.5) 0.57
Data are presented as mean ± standard deviation or n (%).
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rate did not differ between patients who did and did not
receive antibiotics.
Costs
As expected, the total cost of bronchoscopy was lower in
the NIM group than in the IM group (€46 ± 77 vs. 173 ± 0,
p <0.001; Table 5). Mean daily and total antibiotic costs were
lower in the IM group than in the NIM group (€17 ± 24 vs.
€21 ± 20, p = 0.019; and €194 ± 355 vs. €300 ± 335,
p = 0.006). However, overall, the mean total cost of manage-
ment (bronchoscopy-related and antibiotic costs) did not dif-
fer signiﬁcantly between the two groups (€367 ± 355 in the
IM group vs. €346 ± 363 in the NIM group; p = 0.08).
Discussion
In this single-centre randomized study, the 28-day clinical
cure rate among patients with NP did not differ between
patients treated with an invasive strategy and those treated
with a non-invasive strategy. The 28-day mortality rate
tended to be lower with the NIM strategy (10.0% vs. 21.9%
in the IM group), but the difference did not reach statistical
signiﬁcance. Overall management costs did not differ
between the two strategies.
Management of NP outside the ICU setting is poorly doc-
umented, whereas abundant [18] and sometimes controver-
sial [19] data are available concerning the management of
VAP. The high mortality rate of VAP (approximately 30%
[20]) is one reason for using invasive aetiological diagnostic
techniques. Mortality among non-intubated patients with NP
is appreciably lower, i.e. between 6.5% [21] and 14–15%
[5,6,8]. The use of invasive diagnostic strategies for NP out-
side the ICU may have several disadvantages, including high
costs, signiﬁcant morbidity (pneumothorax or bronchial
bleeding), false-negative results, and signiﬁcant delays (24–
48 h) before the results of bacterial culture are available.
Bronchoscopy also requires specialized equipment and
trained personnel. Previous studies of bronchoscopy in gen-
eral medical wards show that it can cause signiﬁcant cardio-
vascular changes, especially in elderly patients [22]. In one
study [23], major complications ensued in 5% of 40 coronary
patients undergoing bronchoscopy, mainly for diagnosis of
NP. On the other hand, a large review of complications dur-
ing 4273 bronchoscopy procedures performed at a university
hospital (52% for diagnosis of suspected infection) found no
bronchoscopy-related deaths. Major complications (pneumo-
thorax or bronchial bleeding) occurred in 0.6% of cases [24].
These drawbacks probably explain the rarity of studies of
invasive NP management outside the ICU [8].
As is the case for VAP, non-invasive management of NP
may nevertheless have potentially harmful consequences:
patients may receive unnecessary or potentially toxic antibi-
otics, resistant microorganisms may be selected, and diagno-
sis of a non-infectious cause of fever and pulmonary
inﬁltration may be delayed [7]. The use of invasive diagnostic
tests for NP in non-intubated patients establishes the distinc-
tion between members of the normal oropharyngeal ﬂora
and species colonizing hospital patients, who are often vul-
nerable because of comorbidities [5]. Moreover, both crude
and attributable NP-related mortality rates have been
reported to be higher in patients who do not receive appro-
priate antibiotics than in patients who do [5].
The mortality data from this study are similar to those
reported in patients with VAP. Sanchez-Nieto et al. [25]
compared NIM and IM strategies in 51 patients with VAP,
and observed respective crude mortality rates of 25.9% (7/
27) and 45.8% (11/24); the difference was not signiﬁcant but,
as in this study, there was a trend towards lower mortality
in the NIM group. However, as the authors pointed out
[25], their population was relatively small. This is also a limi-
tation of the present study and means that a type II error
cannot be ruled out. The trend towards a higher mortality
rate in the IM group, although not signiﬁcant, should there-
fore be conﬁrmed in larger studies.
Invasive management of NP in non-intubated patients led
to less antibiotic consumption. In the IM group, one-quarter
of PSB results were negative, and therefore the correspond-
ing patients did not receive antibiotics. The mortality rate in
this latter subgroup was not signiﬁcantly different from that
in the overall population. The lower use of unnecessary
empirical antibiotic therapy should theoretically limit the
emergence of resistant microorganisms. However, although
the attending physicians were advised to comply with current
ATS guidelines [2], there was no further attempt to inﬂuence




group (n = 34)
Invasive
management
group (n = 34) p
Antibiotic administration, n (%) 34 (100) 26 (76.5) 0.003
Antibiotic treatment days,
mean ± SD
15.1 ± 6.9 10.4 ± 8.6 0.014
Number of antibiotics used,
mean ± SD
2.4 ± 1.1 1.9 ± 1.6 0.14
Daily antibiotic cost, mean ± SD 21.4 ± 20.0 16.5 ± 23.7 0.019
Total antibiotic cost, mean ± SD 300.4 ± 334.5 194.2 ± 354.9 0.006
Costs of bronchoscopy,
mean ± SD
45.7 ± 77.2 172.5 ± 0.0 <0.001
Total costs (bronchoscopy
and antibiotics), mean ± SD
346.1 ± 363.2 366.7 ± 354.9 0.08
SD, standard deviation.
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the choice of antibiotic regimens by the clinical team. As
shown elsewhere [26], physicians are probably more likely
to withhold antibiotics if they know that PSB may provide an
aetiological diagnosis.
Heyland et al. compared 92 patients who underwent bron-
choscopy for clinical signs of VAP and 49 similar patients
who did not undergo that procedure. One of their main
ﬁndings was that the invasive strategy appeared to increase
the physicians’ conﬁdence in the diagnosis and management
of VAP, allowing them to limit or discontinue antibiotic
treatment [26].
The fact that the attending physicians were relatively free
to choose the antibiotic regimen is a limitation of the pres-
ent study. However, although other multicentre studies care-
fully monitored antibiotic prescription by the clinical teams
[7,27], practical constraints are likely to limit such a monitor-
ing [28].
In the present study, however, ﬁrst-line antimicrobial ther-
apy was not adjusted more often in the IM group than in the
NIM group. A multicentre study conducted in Canadian ICUs
led to similar ﬁndings [27].
Antibiotics prescribed for nosocomial infections account
for a signiﬁcant fraction of hospital expenditure. To our
knowledge, the costs related to NP management have not
previously been studied in a medical ward. A study con-
ducted in Argentinian ICUs showed that each case of NP led
to mean extra antibiotic costs of £995 [29]. Although in the
present study antibiotic costs were signiﬁcantly lower in the
IM group than in the NIM group, overall costs (bronchos-
copy plus antibiotic treatment) did not differ signiﬁcantly
between the two groups. Similar data have been obtained in
studies of patients with NP after chest trauma: systematic
bronchoscopy for bacteriological studies reduced antibiotic
costs, but this reduction was compensated for by the cost of
the examinations [30]. Most of the difference in antibiotic
costs in the present study was due to the fact that antibiot-
ics were not administered to invasively managed patients in
whom no pathogen was isolated, and to the shorter duration
of treatment in the IM group.
We conclude that, whether evaluated in terms of patient
outcome or in terms of cost, invasive management of NP
does not appear to be justiﬁed in medical wards. However,
this must be conﬁrmed in larger prospective multicentre
studies.
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